Parkinson’s Disease


Parkinson’s disease is a motor system disorder resulting from the loss of dopamine producing brain cells. This loss of dopamine affects normal nerve cell activity in motor regions of the brain, leaving sufferers unable to control their movements. The primary symptoms of Parkinson’s disease are tremors in hands, arms, legs and head; muscle rigidity that leaves the body stiff and the face expressionless; slowness of movement; and impaired balance and coordination.


More than 4 million people worldwide suffer from Parkinson’s disease and almost all are elderly. Annual drug sales to combat this disease are in excess of $ 5 billion.

L-dopa drugs are commonly used to treat Parkinson’s disease to compensate for missing dopamine. L-dopa is particularly effective in the early treatment stage, however, in the long term, L-dopa not only stops working but also causes side-effects in forms of involuntary movements and psychosis.

Clera approach

Clera is developing an add-on treatment to improve the efficacy of anti-parkinson's disease treatment. CLR4001 has just completed a successful Phase IIa clinical trial. The compound has a unique mechanism of action which diminishes the scope and symptoms of Parkinson's without tolerance or dyskinesia developing.